ECSP22097203A - Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso - Google Patents

Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso

Info

Publication number
ECSP22097203A
ECSP22097203A ECSENADI202297203A ECDI202297203A ECSP22097203A EC SP22097203 A ECSP22097203 A EC SP22097203A EC SENADI202297203 A ECSENADI202297203 A EC SENADI202297203A EC DI202297203 A ECDI202297203 A EC DI202297203A EC SP22097203 A ECSP22097203 A EC SP22097203A
Authority
EC
Ecuador
Prior art keywords
neoantigen
complex
methods
antibodies directed
classical hla
Prior art date
Application number
ECSENADI202297203A
Other languages
English (en)
Spanish (es)
Inventor
Katherine Upchurch-Ange
Jon Weidanz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22097203A publication Critical patent/ECSP22097203A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ECSENADI202297203A 2020-06-01 2022-12-23 Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso ECSP22097203A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032886P 2020-06-01 2020-06-01
US17/199,258 US11976120B2 (en) 2020-06-01 2021-03-11 Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use

Publications (1)

Publication Number Publication Date
ECSP22097203A true ECSP22097203A (es) 2023-02-28

Family

ID=78829884

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202297203A ECSP22097203A (es) 2020-06-01 2022-12-23 Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso

Country Status (18)

Country Link
US (2) US11976120B2 (https=)
EP (1) EP4157884A4 (https=)
JP (1) JP7653513B2 (https=)
KR (1) KR20230019469A (https=)
CN (1) CN116157157A (https=)
AU (1) AU2021283201A1 (https=)
BR (1) BR112022023933A2 (https=)
CA (1) CA3174102A1 (https=)
CL (1) CL2022003299A1 (https=)
CO (1) CO2022018430A2 (https=)
CR (1) CR20220650A (https=)
DO (1) DOP2022000265A (https=)
EC (1) ECSP22097203A (https=)
IL (1) IL298061A (https=)
JO (1) JOP20220308A1 (https=)
MX (1) MX2022015129A (https=)
PE (1) PE20230374A1 (https=)
WO (1) WO2021247608A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210253713A1 (en) * 2018-07-23 2021-08-19 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US20240415884A1 (en) * 2022-02-01 2024-12-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Molecules that bind to cd276 polypeptides
CN120077068A (zh) * 2022-08-18 2025-05-30 英美偌科有限公司 多结构域结合分子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
EP1872124A4 (en) * 2005-04-19 2008-06-11 Prediction Sciences Llc DIAGNOSIS MARKET FOR BREAST CANCER TREATMENT AND PROGRESSION AND METHOD OF USE THEREOF
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2010019921A2 (en) * 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
EP2699603B1 (en) 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
CN103773775B (zh) 2014-01-26 2015-11-18 江苏省农业科学院 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
US10329348B2 (en) 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
US10544220B2 (en) 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
EP3475706B1 (en) 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
EP3573997A4 (en) 2017-01-24 2020-12-09 Abexxa Biologics, Inc. METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER
CN112351795A (zh) 2018-02-23 2021-02-09 安贝科思生物制剂公司 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
US20210253713A1 (en) 2018-07-23 2021-08-19 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use

Also Published As

Publication number Publication date
DOP2022000265A (es) 2023-01-15
CN116157157A (zh) 2023-05-23
AU2021283201A1 (en) 2023-02-02
KR20230019469A (ko) 2023-02-08
JP2023530037A (ja) 2023-07-12
CA3174102A1 (en) 2021-12-09
US20220033504A1 (en) 2022-02-03
PE20230374A1 (es) 2023-03-06
JP7653513B2 (ja) 2025-03-28
IL298061A (en) 2023-01-01
EP4157884A1 (en) 2023-04-05
MX2022015129A (es) 2023-03-24
JOP20220308A1 (ar) 2022-11-15
CL2022003299A1 (es) 2023-07-07
CO2022018430A2 (es) 2022-12-30
EP4157884A4 (en) 2024-06-19
WO2021247608A1 (en) 2021-12-09
BR112022023933A2 (pt) 2023-04-11
US20230303701A1 (en) 2023-09-28
CR20220650A (es) 2023-05-25
US11976120B2 (en) 2024-05-07

Similar Documents

Publication Publication Date Title
ECSP22097203A (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
CO2022018426A2 (es) Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso
MX2020007880A (es) Anticuerpos de mica/b y metodos de uso.
AR122502A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
AR069797A1 (es) Anticuerpos especificos bivalentes
ECSP21026339A (es) Anticuerpos anti–hla–g, composiciones que comprenden anticuerpos anti–hla–g y métodos de uso de anticuerpos anti–hla–g
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
CL2008003779A1 (es) Anticuerpo bivalente bioespecifico que consta de las cadenas ligeras y pesadas de anticuerpos que se une a un primer y segundo antigeno, en el que los dominios constantes cl y ch1 y variables vl y vh, de las cadenas del anticuerpo para el segundo antigeno, se reemplazan entre si; metodo de producción; composición farmaceutica.
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CL2020002539A1 (es) Anticuerpos multiespecíficos anti-hla-g y utilización de los mismos
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
CL2008003781A1 (es) Anticuerpo bivalente biespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un antigeno, y la cadena ligera y pesada de un anticuerpo que se une a un antigeno diferente, donde los dominios variables vl y vh estan cambiados el uno por el otro; metodo de preparacion; celula huesped; y composicion.
PY1829572A (es) Dominios de unión a antígeno humanizados y métodos de uso
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
CO2017005388A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
PE20211887A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
MX360707B (es) Receptor antigénico quimérico.
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
MX395074B (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos
CO2023011463A2 (es) Nuevos anticuerpos anti-cd24
MX2019007984A (es) Apareamiento preferido de dominios de anticuerpos.
MX394735B (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
CO2023009279A2 (es) Moléculas de unión a gucy2c y sus usos